Trial Profile
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2023
Price :
$35
*
At a glance
- Drugs Tezepelumab (Primary)
- Indications Allergic asthma; Asthma
- Focus Registrational; Therapeutic Use
- Acronyms PATHWAY
- Sponsors Amgen; MedImmune
- 07 Nov 2023 Results of pooled analysis from pooled analysis of the PATHWAY and NAVIGATOR , published in the Annals of Internal Medicine
- 13 Sep 2023 Results of post-hoc pooled analysis from PATHWAY (NCT02054130) and NAVIGATOR(NCT03347279) studies assessing the effect of tezepelumab on pre-BD ppFEV1 in patients grouped by baseline pre-BD ppFEV1 presented at the 33rd Annual Congress of the European Respiratory Society.
- 24 May 2023 Results assessing efficacy of tezepelumab in patients grouped by baseline ppFEV1 using pooled data from the PATHWAY and NAVIGATOR studies, presented at the 119th International Conference of the American Thoracic Society.